However, the possibility of using the intravitreal DEX implant as a first line of treatment or making a switch from anti-VEGF therapy in case of refractory macular edema must be highly considered to guarantee maximum visual recovery and the least retinal damage to the patient. The gene discussed is VEGFA; the disease is macular retinal edema.